GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 2,731 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 2,731 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $94.73, for a total value of $258,707.63. Following the sale, the chief executive officer now owns 7,752 shares in the company, valued at approximately $734,346.96. This represents a 26.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.
• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $805,951.75.

GeneDx Stock Down 2.8 %

GeneDx stock traded down $2.49 during trading hours on Tuesday, reaching $87.17. The stock had a trading volume of 1,014,754 shares, compared to its average volume of 607,372. The company has a market cap of $2.45 billion, a price-to-earnings ratio of -44.47 and a beta of 1.90. The business’s 50 day moving average price is $83.51 and its 200-day moving average price is $68.32. GeneDx Holdings Corp. has a 52 week low of $7.72 and a 52 week high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.04 by $0.66. The firm had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Wall Street Analysts Forecast Growth

WGS has been the subject of a number of research reports. The Goldman Sachs Group upped their price objective on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen upped their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $72.33.

Institutional Trading of GeneDx

Several hedge funds and other institutional investors have recently made changes to their positions in WGS. Vanguard Group Inc. increased its position in GeneDx by 18.5% during the 4th quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company’s stock valued at $77,337,000 after buying an additional 156,768 shares in the last quarter. Summit Partners Public Asset Management LLC increased its holdings in shares of GeneDx by 336.9% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock valued at $58,073,000 after acquiring an additional 582,619 shares in the last quarter. William Blair Investment Management LLC purchased a new position in shares of GeneDx in the 4th quarter valued at approximately $51,496,000. Lord Abbett & CO. LLC purchased a new position in shares of GeneDx in the 4th quarter valued at approximately $48,458,000. Finally, Fred Alger Management LLC boosted its stake in GeneDx by 38.5% in the 4th quarter. Fred Alger Management LLC now owns 546,054 shares of the company’s stock worth $41,970,000 after purchasing an additional 151,824 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.